Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16


Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054.

Brys M, Fanning L, Hung S, Ellenbogen A, Penner N, Yang M, Welch M, Koenig E, David E, Fox T, Makh S, Aldred J, Goodman I, Pepinsky B, Liu Y, Graham D, Weihofen A, Cedarbaum JM.

Mov Disord. 2019 Aug;34(8):1154-1163. doi: 10.1002/mds.27738. Epub 2019 Jun 17.


Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models.

Weihofen A, Liu Y, Arndt JW, Huy C, Quan C, Smith BA, Baeriswyl JL, Cavegn N, Senn L, Su L, Marsh G, Auluck PK, Montrasio F, Nitsch RM, Hirst WD, Cedarbaum JM, Pepinsky RB, Grimm J, Weinreb PH.

Neurobiol Dis. 2019 Apr;124:276-288. doi: 10.1016/j.nbd.2018.10.016. Epub 2018 Oct 28.


LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson's Disease Mouse Model.

Zhao HT, John N, Delic V, Ikeda-Lee K, Kim A, Weihofen A, Swayze EE, Kordasiewicz HB, West AB, Volpicelli-Daley LA.

Mol Ther Nucleic Acids. 2017 Sep 15;8:508-519. doi: 10.1016/j.omtn.2017.08.002. Epub 2017 Aug 10.


Public Health Workforce in Switzerland: are public health workers lacking?

Paccaud F, Weihofen A, Frank M.

Int J Public Health. 2013 Dec;58(6):799-800. doi: 10.1007/s00038-013-0508-8. No abstract available.


The mitochondrial intramembrane protease PARL cleaves human Pink1 to regulate Pink1 trafficking.

Meissner C, Lorenz H, Weihofen A, Selkoe DJ, Lemberg MK.

J Neurochem. 2011 Jun;117(5):856-67. doi: 10.1111/j.1471-4159.2011.07253.x. Epub 2011 Apr 13.


Parkin selectively alters the intrinsic threshold for mitochondrial cytochrome c release.

Berger AK, Cortese GP, Amodeo KD, Weihofen A, Letai A, LaVoie MJ.

Hum Mol Genet. 2009 Nov 15;18(22):4317-28. doi: 10.1093/hmg/ddp384. Epub 2009 Aug 13.


Pink1 forms a multiprotein complex with Miro and Milton, linking Pink1 function to mitochondrial trafficking.

Weihofen A, Thomas KJ, Ostaszewski BL, Cookson MR, Selkoe DJ.

Biochemistry. 2009 Mar 10;48(9):2045-52. doi: 10.1021/bi8019178.


Pink1 Parkinson mutations, the Cdc37/Hsp90 chaperones and Parkin all influence the maturation or subcellular distribution of Pink1.

Weihofen A, Ostaszewski B, Minami Y, Selkoe DJ.

Hum Mol Genet. 2008 Feb 15;17(4):602-16. Epub 2007 Nov 14.


Dopamine covalently modifies and functionally inactivates parkin.

LaVoie MJ, Ostaszewski BL, Weihofen A, Schlossmacher MG, Selkoe DJ.

Nat Med. 2005 Nov;11(11):1214-21. Epub 2005 Oct 16.


Consensus analysis of signal peptide peptidase and homologous human aspartic proteases reveals opposite topology of catalytic domains compared with presenilins.

Friedmann E, Lemberg MK, Weihofen A, Dev KK, Dengler U, Rovelli G, Martoglio B.

J Biol Chem. 2004 Dec 3;279(49):50790-8. Epub 2004 Sep 21.


Targeting presenilin-type aspartic protease signal peptide peptidase with gamma-secretase inhibitors.

Weihofen A, Lemberg MK, Friedmann E, Rueeger H, Schmitz A, Paganetti P, Rovelli G, Martoglio B.

J Biol Chem. 2003 May 9;278(19):16528-33. Epub 2003 Mar 5.


Intramembrane-cleaving proteases: controlled liberation of proteins and bioactive peptides.

Weihofen A, Martoglio B.

Trends Cell Biol. 2003 Feb;13(2):71-8. Review.


Identification of signal peptide peptidase, a presenilin-type aspartic protease.

Weihofen A, Binns K, Lemberg MK, Ashman K, Martoglio B.

Science. 2002 Jun 21;296(5576):2215-8.


Intramembrane proteolysis of signal peptides: an essential step in the generation of HLA-E epitopes.

Lemberg MK, Bland FA, Weihofen A, Braud VM, Martoglio B.

J Immunol. 2001 Dec 1;167(11):6441-6.

Supplemental Content

Loading ...
Support Center